of patients, epidemiologists, and specialists in infectious diseases who represent other stakeholders for this project. This multidisciplinary collaboration facilitated the uptake and dissemination of the prior guideline, and it is anticipated that these recommendations will be similarly distributed and used to guide busy clinicians and their patients at the time of THA and TKA. GRADE methodology supports consensusbased recommendations that can be reached based on lowquality evidence across the critical outcomes and transparently rates the strength of the recommendation as well as the quality of the evidence supporting the recommendation Perioperative management of rituximab has been a challenge given the long dosing interval of 6 months and the recognized risk of severe infection linked to its use As previously, the recommendations that form this guideline are not treatment mandates. These recommendations will provide the backbone for a shared decision-making process between patient